A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : BETi

Search Conditions:
Search Keyword : BETi
Search Method : Exact match.
Research Area:

Abbreviation: BETi
Appearance Frequency: 97 time(s)
Long forms: 9

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
BET inhibitors
(41 times)
(16 times)
BET (21 times)
AML (3 times)
AR (3 times)
2014 BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Bromodomain and extra-terminal inhibitors
(39 times)
(19 times)
AML (4 times)
TNBC (3 times)
BET (2 times)
2014 Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.
BET bromodomain inhibitors
(7 times)
(5 times)
PROTAC (2 times)
ARV-771 (1 time)
AURKAi (1 time)
2016 Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
BET protein inhibitors
(3 times)
(1 time)
BET (2 times)
alpha-KG (1 time)
AURKA/B (1 time)
2016 Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
BET proteins
(3 times)
(2 times)
BET (2 times)
AR (1 time)
mCRPC (1 time)
2017 BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.
BET protein bromodomain inhibitor
(1 time)
Cell Biology
(1 time)
BET (1 time)
Myc (1 time)
PanNETs (1 time)
2014 The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
bromodomain and extra-terminal proteins
(1 time)
(1 time)
Bcl-xL (1 time)
TNBC (1 time)
2018 Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
bromodomain protein inhibitor
(1 time)
(1 time)
UC (1 time)
UCC (1 time)
2021 Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment.
enhancer-blocking bromodomain inhibitors
(1 time)
AT (1 time)
BA (1 time)
CL (1 time)
2022 High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma.